-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Divarasib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Divarasib in Non-Small Cell Lung Cancer Drug Details: Divarasib (GDC-6036...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-585 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-585 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-585 in Solid Tumor Drug Details: CDX-585 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Metastatic Brain Tumor Drug Details: GLR-2007 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensartinib Hydrochloride in Pediatric Diffuse Intrinsic Pontine Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ensartinib Hydrochloride in Pediatric Diffuse Intrinsic Pontine Glioma Drug Details: Ensartinib hydrochloride (Bemena) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Non-Small Cell Lung Cancer Drug Details: GLR-2007 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: GLR-2007 is...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus (HPV) Associated Cancer - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus (HPV) Associated Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Drugs In Development, 2023’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...